Nanomedicine therapeutic approaches to overcome cancer drug resistance

被引:763
作者
Markman, Janet L. [1 ]
Rekechenetskiy, Arthur [1 ]
Holler, Eggehard [1 ,2 ,3 ]
Ljubimova, Julia Y. [1 ,2 ]
机构
[1] Cedars Sinai Med Ctr, Nanomed Res Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA
[2] Arrogene Inc, Santa Monica, CA USA
[3] Univ Regensburg, Dept Biol & Preclin, D-93053 Regensburg, Germany
关键词
Nanobiopolymers; Nanodrug; Drug delivery; Tumor multidrug resistance; PEGYLATED LIPOSOMAL DOXORUBICIN; CELL LUNG-CANCER; MEDIATED PACLITAXEL RESISTANCE; ACUTE MYELOID-LEUKEMIA; TUMOR STEM-CELLS; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; BREAST-CANCER; ACID NANOBIOCONJUGATE; LOADED NANOPARTICLES;
D O I
10.1016/j.addr.2013.09.019
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Nanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the treatment efficacy while reducing detrimental side effects to normal tissues. Cancer drug resistance is a complicated process that involves multiple mechanisms. Here we discuss the major forms of drug resistance and the new possibilities that nanomedicines offer to overcome these treatment obstacles. Novel nanomedicines that have a high ability for flexible, fast drug design and production based on tumor genetic profiles can be created making drug selection for personal patient treatment much more intensive and effective. This review aims to demonstrate the advantage of the young medical science field, nanomedicine, for overcoming cancer drug resistance. With the advanced design and alternative mechanisms of drug delivery known for different nanodrugs including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles, overcoming various forms of multi-drug resistance looks promising and opens new horizons for cancer treatment. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1866 / 1879
页数:14
相关论文
共 149 条
[1]
Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]
Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[3]
Gold nanoparticles: opportunities and challenges in nanomedicine [J].
Arvizo, Rochelle ;
Bhattacharya, Resham ;
Mukherjee, Priyabrata .
EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (06) :753-763
[4]
Co-delivery of Doxorubicin and PSC 833 (Valspodar) by Stealth Nanoliposomes for Efficient Overcoming of Multidrug Resistance [J].
Bajelan, Elmira ;
Haeri, Azadeh ;
Vali, Amir Masoud ;
Ostad, Seyed Nasser ;
Dadashzadeh, Simin .
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2012, 15 (04) :568-582
[5]
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells [J].
Bentires-Alj, M ;
Barbu, V ;
Fillet, M ;
Chariot, A ;
Relic, B ;
Jacobs, N ;
Gielen, J ;
Merville, MP ;
Bours, V .
ONCOGENE, 2003, 22 (01) :90-97
[6]
Inorganic Nanoparticles in Cancer Therapy [J].
Bhattacharyya, Sanjib ;
Kudgus, Rachel A. ;
Bhattacharya, Resham ;
Mukherjee, Priyabrata .
PHARMACEUTICAL RESEARCH, 2011, 28 (02) :237-259
[7]
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[8]
BORSELLINO N, 1995, CANCER RES, V55, P4633
[9]
Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236
[10]
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers [J].
Burger, J. A. ;
Peled, A. .
LEUKEMIA, 2009, 23 (01) :43-52